The Company (Acquisition) (Details)	6 Months Ended	0 Months Ended		12 Months Ended		0 Months Ended
	Jun. 30, 2013 USD ($)	Jun. 11, 2013 Synacthen [Member] USD ($)	Jan. 18, 2013 BioVectra [Member] USD ($)	Dec. 31, 2013 BioVectra [Member] CAD	Jan. 18, 2013 BioVectra [Member] CAD	Jun. 11, 2013 Maximum [Member] Synacthen [Member] USD ($)
Business Acquisition [Line Items]
Upfront consideration paid		$ 60,000,000
Annual cash payments		25,000,000
Annual payments secured by a letter of credit		75,000,000
Total payment						300,000,000
Percentage of voting interest acquired					100.00%
Total cash paid for acquisition of BioVectra	50,803,000		50,315,000
Maximum additional cash consideration					50,000,000
Number of years financial results are based on			3 years
Estimated fair value of contingent consideration	30,383,000		30,383,000
Additional cash consideration paid				5,000,000